1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Transition at Teva: Blockbuster drug Copaxone to lose patent protection in 2014

Introduction

In October 2013, Teva announced that it would be cutting approximately 10% of the workforce in order to cut costs. Later that month, it announced the departure of its CEO of just 18 months, Jeremy Levin, who was forced out by Chairman Phillip Frost. This case study looks out how Teva, one of the largest pharmaceuticals companies in the world, has ended up in this position, & what the future holds

Features and benefits

* This case study looks at Teva's operations and the market in which it operates. It also looks in detail at Copaxone, Teva's best-selling drug.
* The case study examines the M&A activity Teva has been involved in over recent years, and whether or not it has been successful.
* Teva's future engines of growth are discussed, as well as 2 outlooks for 2014, depending on generic competition for Copaxone.

Highlights

In the US, one in every seven prescriptions is filled with a Teva product, and in the UK, this rises to one in every six prescriptions. The company operates in over 60 countries worldwide and employs approximately 45,000 people. Teva has over 55,000 product variants and 1,000 molecules, and manufactured 64 billion tablets and capsules in 2013.
Copaxone is one of Teva's best-selling drugs, with global sales of $3.9bn in 2012 and $4.3bn in 2013. Copaxone accounted for 49% of the specialty drugs segment's sales in 2012, rising to 52% in 2013. However, Copaxone may face generic competition as early as May 2014.
The New Therapeutic Entities (NTE) program, launched in December 2012, uses existing, known molecules that can offer improvements for patients by being formulated, delivered or used in a novel way. Development of NTEs is less time consuming, less risky, and less expensive.

Your key questions answered

* Why is Copaxone losing patent protection and what is Teva doing to alleviate this?
* What is the NTE program?
* What is the outlook for Teva in 2014?

Table Of Contents

Transition at Teva: Blockbuster drug Copaxone to lose patent protection in 2014
OVERVIEW
Catalyst
Summary
TEVA PHARMACEUTICALS IS A LEADER IN GENERIC PHARMACEUTICALS
Teva is a global generics giant
Generic drugs are cheap and effective versions of branded drugs
Teva operates through three segments: generics, specialty, and other
Teva is a global powerhouse in generic medicine
The specialty segment is the second largest, with revenues of $8.4bn in 2013
The other segment accounts for 10% of sales
COPAXONE'S PATENT PROBLEMS AND POOR MandA ACTIVITY HAVE AFFECTED TEVA
Copaxone faces losing its patent in 2014
Teva is losing its patent early
Teva is attempting to move existing Copaxone patients to its new version
A string of questionable acquisitions has severely impacted Teva
NTE DEVELOPMENT AND INTEGRATED GENERIC AND RandD ORGANIZATION ARE PRIMARY ENGINES OF GROWTH
Teva's NTE program finds advances on existing therapies
The NTE program has several benefits which could propel growth for Teva
Teva is extremely optimistic about its NTE program
Analysts are unenthusiastic about Teva's strategy
Teva has an appetite for "game-changing deals"
TEVA IN TRANSITION
Change at Teva is causing ripples in the stock market
Teva anticipates two outlooks for 2014
The "Generic Copaxone" scenario assumes the launch of at least two generic competitors to Copaxone in June 2014
The "Exclusive Copaxone" scenario assumes no generic competition to Copaxone in June 2014
Teva is aggressive in its efforts to stave off generic competition
Teva plans to focus on NTE, RandD, and cost reduction
CONCLUSIONS
Teva has attempted to mitigate the loss of Copaxone's patent
APPENDIX
Definitions
Sources
Further Reading
Ask the analyst
About MarketLine
Disclaimer

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.